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Abstract
Biomarkers of inherited tubulopathies would be useful for clarifying diagnoses in patients where genetic screening is not 
readily available or where disease-attributable mutations are not found. Urinary extracellular vesicles (uEVs) obtained by 
ultracentrifugation can be used as a source of biomarkers for inherited tubulopathies such as Gitelman Syndrome (GS), 
however, ultracentrifugation requires costly equipment and is thus not usually accessible. In contrast, precipitation methods 
can extract uEVs using standard laboratory centrifuges, thus making uEVs extracted by this method clinically tractable as a 
source of biomarkers for GS and other inherited tubulopathies. Here we optimise a precipitation method for extracting urinary 
extracellular vesicles (uEVs) and provide proof of concept that these uEVs are a source of biomarkers using GS an exem-
plar tubulopathy. For method optimisation, uEVs were precipitated from fresh and frozen (for up to 6 years), small volume 
(1–2 mL) urine samples from healthy volunteers and GS patients. Nanoparticle tracking analysis was used to calculate the 
concentration of uEVs. Thiazide sensitive sodium-chloride cotransporter (NCC) content was determined by densitometry 
of Western blots. NCC content of uEVs was lower in GS patients (n = 11) than healthy volunteers (n = 12; P = 0.001). Three 
of four patients clinically suspected for GS, in whom only a single SLC12A3 mutation was identified, had lower uEV NCC 
content than all healthy volunteers tested. In the clinical setting, sufficient uEVs can be extracted from frozen, small volume 
urine samples using precipitation methods to distinguish patients with GS from healthy volunteers, and thus this source of 
uEVs could be utilised as an additional diagnostic test for GS and similar disorders.
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Introduction
Inherited tubulopathies are rare transporter disorders of 
renal tubular epithelia causing defective renal handling of 
electrolytes, amino-acids, water and/or glucose. In Gitelman 
Syndrome (GS; loss of thiazide-sensitive sodium-chloride 
cotransporter function), genetic testing has a reported clini-
cal sensitivity of only 65–80% [1], therefore identification of 
biomarkers of inherited tubulopathies (including GS) would 
be useful in patients where there is clinical doubt and/or 
where genetic testing is not readily available.
Urinary extracellular vesicles (uEVs) are a poten-
tially rich source of biomarkers for tubulopathies, since 
their membranes are composed of apical proteins from 
all nephron segments [2]. Thiazide-sensitive sodium-
chloride cotransporter (NCC) abundance within uEVs of 
GS patients obtained by ultracentrifugation is reduced on 
Western blot [3, 4]; however, ultracentrifugation requires 
costly equipment, and so this method of uEV extraction 
would not be easily accessible to clinicians for diagnostic 
purposes. Commercially available kits allow extraction of 
uEVs by precipitation using standard laboratory centri-
fuges; this might make the use of uEVs as a source of bio-
markers more widely applicable and clinically tractable. 
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Here we provide proof of concept that uEVs extracted by 
precipitation from small-volume urine samples can be so 
used, using GS as an exemplar tubulopathy. Therefore, 
this technique could be adapted to yield a clinically tracta-
ble additional diagnostic test for GS and potentially other 
tubulopathies.
Materials and methods
The Exiqon miRCURY Exosome Isolation Kit (#300102) 
was used according to manufacturer protocol for extrac-
tion of uEVs, with the addition of a filtration step (0.22 µm 
filter, Millipore Stericup 250) after harvesting of the initial 
supernatant, and resuspension of the final pellet containing 
uEVs in 50 µL of resuspension buffer (rather than 100 µL). 
We evaluated a modification to the standard protocol with 
the aim of increasing uEV yield; fresh urine samples 
without dipstick abnormalities (Siemens Multistix 10SG) 
were collected from healthy volunteers into sterilised glass 
bottles and incubated with precipitation buffer, either 
overnight or for the manufacturer-recommended time of 
60 min, at 4 °C. Total protein concentrations of uEV prep-
arations were measured using a bioinchoninic acid (BCA) 
method (Pierce™ BCA Protein Assay Kit, Thermo Sci-
entific), and particle numbers determined by nanoparticle 
tracking analysis on a Nanosight NS500 (Supplementary 
Figure 1, Malvern, UK). Comparisons between 60 min and 
overnight incubation, and precipitation and ultracentrifu-
gation were made using the Wilcoxon signed-rank test; 
data are presented as median [range].
To provide proof of concept that uEVs could be used 
as a source of biomarkers in inherited tubulopathies, 
azide-preserved small volume (1–2 mL) urine samples 
from healthy volunteers and patients with GS, stored 
at − 80 °C, were obtained from the sample bank of the 
Cambridge Renal Genetic and Tubular Disorders service. 
Samples were collected under Cambridgeshire Research 
Ethics Committee approval (08-H0306-62) with informed 
consent of participants. Protease inhibitors (Roche cOm-
plete, EDTA-free) were added at the point of thawing. 
Since cooling increases uromodulin polymerisation [5], 
samples were alkalinised by addition of 1 M NaOH to 
pH 8.1 (determined using MColorpHast™ pH indicator 
strips) prior to processing, to reverse this tendency [6] and 
maximise uEV yield.
To exclude an adverse effect of alkalinisation on protein 
and uEVs extraction by precipitation, further fresh urine 
samples were collected from healthy volunteers (n = 9) and 
divided into two aliquots, one of which was alkalinised (as 
per protocol above) prior to processing. Protein and particle 
yields were compared using the Wilcoxon signed rank test.
Results
Overnight incubation of samples with precipitation buffer sig-
nificantly increased particle concentration within uEV prepara-
tions (1.6 × 1010/mL [0.3–3.5 × 1010/mL] vs. 0.07 × 1010/mL 
[0.03–0.2 × 1010/mL]; P = 0.03), hence overnight incubation 
was performed thereafter. Total protein content of uEV prep-
arations was unchanged (3.8 [3.1–5.1] vs. 3.3 [1.8–6.4] µg/
mL; n = 6, P = 0.3). The presence of uEVs within preparations 
obtained by precipitation was confirmed by Western blotting 
for CD9 and TSG101 (Supplementary Figure 2).
The precipitation method yielded a similar quantity of pro-
tein and uEVs (on a per mL urine basis) compared to ultra-
centrifugation (as per our previously published protocol [7]); 
protein contents were 0.7–10.8 µg (0.7–10.8 µg/mL urine) 
and 12.1–50.8 µg (0.2–0.8 µg/mL urine) in uEV preparations 
produced by precipitation and ultracentrifugation respectively 
(n = 3; P = 0.2). Total number of uEVs from these preparations 
were 6.2–28.0 billion and 1.0–27.8 billion particles/mL urine 
respectively (n = 3; P = 0.4).
Protein content of uEV preparations obtained from frozen 
samples (used as surrogate marker of uEV quantity) ranged 
from 1.2 to 30.9 µg. Thirty microlitre aliquots of uEV prepa-
rations were reduced and separated by 4–12% SDS-PAGE 
(NuPAGE, Thermo Fisher) prior to transfer to nitrocellulose 
membranes (Bio-Rad). Membranes were blocked with 5% 
skimmed milk in 0.1% PBS-Tween 20, and incubated with 
primary (anti-NCC [Abcam, ab95032], anti-CD9 [Abcam, 
ab92729] or anti-TSG101 [Abcam, ab83]) and secondary 
 (IRDye® or HRP-conjungated) antibodies (Dako). Bands of 
appropriate size were observed using an infrared imaging 
system (LICOR Odyssey) or on radiographic film (follow-
ing addition of chromographic reagent), and densitometry 
performed using ImageJ software (NIH, USA). Comparisons 
between groups were made using the Mann–Whitney U test.
NCC content of uEVs, normalised to quantity of protein 
loaded, was significantly lower in GS patients (n = 11) than 
healthy volunteers (n = 12; P = 0.001, Fig. 1). Three of four 
patients clinically suspected to have GS, but in whom only a 
single SLC12A3 mutation was identified, also had lower uEV 
NCC content than all healthy volunteers tested (Fig. 1).
Alkalinisation did not adversely affect either protein con-
centration (non-alkalinised 3.9 µg/mL [1.0–6.6 µg/mL], alka-
linised 4.8 µg/mL [0.9–9.1 µg/mL]; n = 9; P = 0.25) or particle 
yield (non-alkalinised 2.3x1010 [2.4 × 109 – 4.2 × 1010] parti-
cles/mL, alkalinised 1.4 × 1010 [5.3 × 108 – 3.2 × 1010] parti-
cles/mL; P = 0.13).
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Discussion
This study demonstrates that sufficient uEVs can be 
extracted from small volume urine samples by precipitation 
methods for immunoblotting studies. To the authors’ knowl-
edge, this is the first study to demonstrate that the quantity of 
NCC present within uEVs extracted by precipitation is lower 
in patients with GS than in healthy volunteers. Furthermore, 
the abundance of NCC within uEVs of most patients sus-
pected of GS but without a confirmed genetic diagnosis was 
also low, thus indicating that this method could be a useful 
additional test for GS in patients in which a diagnosis is not 
reached by genetic testing. These findings concur with those 
of a previous study which evaluated uEVs extracted from GS 
patients by ultracentrifugation [3]. Further studies to com-
pare the uEVs extracted using both techniques would be of 
potential interest, but clinicians are unlikely to have routine 
access to ultracentrifuges, so that technique is not general-
izable. The main advantage of the precipitation technique 
validated here is that extraction of uEVs can be performed 
using standard laboratory centrifuges, thus making uEVs 
a widely accessible and clinically tractable source of bio-
markers for GS and other inherited tubulopathies. These are 
encouraging data, and further refinement and investigation 
of this technique as a diagnostic test for GS is warranted.
Normalised NCC abundance within uEV preparations of 
some GS patients was similar to healthy volunteers, perhaps 
reflecting expression of some mutant NCC proteins at the 
apical membrane, and thus within uEVs [8]. It is recognised 
that suitable normalisation of uEVs is problematic because 
no single parameter can specifically quantify EVs; and EV 
subtypes from different nephron segments will express dif-
ferent markers [9]. We used total protein for this purpose 
because it is a clinically accessible surrogate marker for all 
uEVs, and our aim was to demonstrate proof of concept for 
a clinically tractable test. Although we acknowledge that 
total protein is a non-specific surrogate marker of uEV num-
ber, we would have expected that using it would if anything 
decrease the likelihood of identifying a significant difference 
between the normalised NCC content of healthy volunteers 
and GS patients as in the present study. The main limitation 
of our study was the relatively small number of GS patient 
samples included in the proof of concept study, which 
reflects the ultra-rarity of GS in the population (predicted 
prevalence approximately 1:40,000 [1]). However, our study 
was still adequately powered to demonstrate a significant 
difference in the NCC content of uEVs between GS patients 
and healthy volunteers.
Our technique could also improve characterisation of the 
molecular bases of other inherited renal tubulopathies. For 
example, excretion of aquaporin-2 (AQP2) within uEVs cor-
relates with AQP2 expression in the kidneys of humans and 
rats [4, 10], suggesting that the uEV proteome is a surrogate 
marker for expression of apical proteins within the nephron. 
That said, hydration status affects AQP2 expression, so even 
this protein would not be reliable as a denominator of EV 
amount in healthy volunteers. Excretion of various proteins 
within uEVs of humans and rats has been reported [4, 10], 
and the precipitation techniques utilised here will allow 
future studies of the uEV proteome to be performed using 
Fig. 1  a Representative western blot of urinary extracellular vesi-
cle (uEV) preparations, obtained from small volume urine samples 
from healthy volunteers (HV) and patients with genetically con-
firmed Gitelman Syndrome (GS), for the thiazide sensitive sodium-
chloride cotransporter (NCC). Expected size is ~ 111 kDa (indicated 
by the black arrow). Molecular size markers (in kDa) are shown in 
the right hand lane. uEVs were extracted from 1 to 2 mL urine sam-
ples, previously stored at − 80  °C, by precipitation. b Scatter graph 
showing densitometry results from Western blot for the thiazide sen-
sitive sodium-chloride cotransporter (NCC) in urinary extracellu-
lar vesicles (uEVs) obtained from small volume urine samples from 
healthy volunteers, patients with confirmed Gitelman Syndrome (GS) 
based on genetic testing, and patients clinically suspected to have GS 
for which only one known mutation of SLC12A3 could be identified 
(GS 1 allele). Densitometry readings for NCC were normalised to the 
amount of protein loaded (in µg). uEV NCC content was significantly 
lower in GS patients compared to healthy volunteers (P = 0.001)
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urine samples of lower volume. This could be also particu-
larly beneficial when studying animal models in which urine 
volumes are low.
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